|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,583,141: Scope, Claims, and Landscape
U.S. Patent 5,583,141, titled "Novel Bicyclic Compounds," describes a class of compounds and their therapeutic applications, primarily related to their efficacy as potassium channel modulators. The patent claims a significant scope of chemical structures and their use in treating conditions influenced by potassium channel activity, including cardiovascular disorders, neurological conditions, and certain inflammatory diseases. The patent landscape indicates a foundational role for these compounds, with subsequent innovations building upon or seeking to circumvent its broad claims.
What is the Core Invention of U.S. Patent 5,583,141?
The core invention detailed in U.S. Patent 5,583,141 encompasses a specific series of novel bicyclic organic compounds. These compounds are characterized by a particular ring structure designed to interact with potassium channels. The patent explicitly defines the chemical structure and its variations through Markush claims, allowing for a broad interpretation of the protected chemical space. The primary therapeutic utility identified is the modulation of potassium channel activity, which is crucial for cellular excitability and function across various physiological systems.
What are the Key Claims of Patent 5,583,141?
U.S. Patent 5,583,141 contains multiple claims that define the protected intellectual property. These claims delineate the chemical entities themselves, their pharmaceutical compositions, and their methods of use for treating specific medical conditions.
-
Claim 1: This independent claim defines the bicyclic compounds. It describes a core bicyclic structure with various substituents at defined positions. The claim is written as a Markush claim, specifying a generic formula (I) that encompasses a wide array of specific chemical structures falling within the described framework. The substituents (R1, R2, R3, R4, and Ar) are defined with multiple options, creating a broad scope for the protected chemical entities.
-
Claim 14: This claim recites a pharmaceutical composition. It includes a compound of "any one of claims 1-13" along with a pharmaceutically acceptable carrier. This claim extends protection to the formulated drug product, not just the active pharmaceutical ingredient (API).
-
Claim 15: This independent claim describes a method of treating a potassium channel-related disorder. It involves administering a therapeutically effective amount of a compound as defined in Claim 1 (or a composition of Claim 14) to a subject in need thereof. The patent lists several categories of disorders, including:
- Cardiovascular disorders: Such as hypertension, angina pectoris, and arrhythmias.
- Neurological disorders: Including epilepsy, pain, and neurodegenerative diseases.
- Other conditions: Such as asthma and inflammatory diseases.
-
Dependent Claims (e.g., Claims 2-13, 16-18): These claims narrow the scope of the independent claims by further specifying particular substituents or sub-groups of compounds falling within the generic formula. For example, they might define specific atoms or chemical groups for R1, R2, R3, R4, or Ar, or specify particular counterions for salt forms. These claims provide layered protection, offering more specific embodiments if the broader claims are challenged.
The breadth of Claim 1, particularly through its Markush structure, is a critical aspect of the patent's scope. It covers a large family of related chemical compounds, making it challenging for competitors to develop similar therapeutic agents without infringing on this patent.
What is the Therapeutic Scope of Compounds Claimed in Patent 5,583,141?
The therapeutic scope of the compounds patented under U.S. Patent 5,583,141 is primarily defined by their activity as potassium channel modulators. This mechanism of action underpins their utility in treating a range of conditions where potassium channel function is implicated in disease pathogenesis.
What are the Targeted Medical Conditions?
The patent explicitly lists several categories of medical conditions for which the claimed compounds are intended. These include:
-
Cardiovascular Disorders: The patent identifies hypertension (high blood pressure), angina pectoris (chest pain due to reduced blood flow to the heart), and cardiac arrhythmias (irregular heartbeats) as treatable conditions. The modulation of potassium channels in vascular smooth muscle and cardiac myocytes directly impacts blood pressure and heart rhythm.
-
Neurological Disorders: The patent claims efficacy in treating epilepsy (a disorder characterized by recurrent seizures), pain, and certain neurodegenerative diseases. Potassium channels play vital roles in neuronal excitability, neurotransmitter release, and neuronal survival.
-
Other Diseases: The patent also includes asthma and inflammatory diseases within its therapeutic scope. In asthma, potassium channel modulation can affect airway smooth muscle tone. In inflammatory conditions, potassium channels are involved in the function of immune cells.
The broad categorization of treatable disorders suggests that the inventors envisioned a wide applicability for their potassium channel modulating compounds, leveraging the fundamental role of these channels in cellular physiology.
What is the Patent Landscape for U.S. Patent 5,583,141?
The patent landscape surrounding U.S. Patent 5,583,141 reflects its foundational nature in the field of potassium channel modulators. As an early and broad patent in this area, it has likely influenced subsequent research and patent filings, leading to a complex web of related and potentially competing intellectual property.
How Does Patent 5,583,141 Interact with Later Patents?
-
Follow-on Patents: Numerous later patents likely claim specific novel compounds that fall within the generic scope of Patent 5,583,141 but are not explicitly claimed by their specific structures. These follow-on patents often add further chemical modifications, new therapeutic uses, or improved formulations, aiming to carve out their own distinct intellectual property space while acknowledging the existence of the earlier patent.
-
Improvement Patents: Some patents may focus on improving upon the compounds or methods disclosed in Patent 5,583,141. This could involve developing compounds with enhanced potency, selectivity for specific potassium channel subtypes, better pharmacokinetic profiles (absorption, distribution, metabolism, excretion), or reduced side effects.
-
Method-of-Use Patents: Later patents might claim new therapeutic uses for compounds covered by Patent 5,583,141, especially if novel mechanisms of action or efficacy in previously undisclosed conditions are discovered.
-
Process Patents: Patents related to improved manufacturing processes for synthesizing the claimed compounds can also emerge, offering a different avenue of intellectual property protection.
-
Exclusivity Challenges: Companies seeking to market generic versions of drugs based on the technology protected by Patent 5,583,141 would need to navigate its claims carefully. They might seek to develop non-infringing compounds, argue for the invalidity of certain claims, or wait for the patent to expire. The expiration of Patent 5,583,141, or any key patents that have relied on its principles, opens the door for generic competition.
The original patent's broad claims can act as a significant barrier to entry for new entrants in the potassium channel modulator space. Understanding the full breadth of its claims and how they have been interpreted or potentially narrowed by subsequent court decisions or re-examinations is critical for any entity operating in this therapeutic area.
What is the Expected Exclusivity Period for Patent 5,583,141?
The expected exclusivity period for U.S. Patent 5,583,141 is determined by its original grant date and potential extensions.
-
Original Term: U.S. patent term is generally 20 years from the filing date. Patent 5,583,141 was filed on May 17, 1995, and granted on November 19, 1996. Therefore, its original term expired on May 17, 2015 (20 years from the filing date).
-
Patent Term Adjustment (PTA): The U.S. Patent and Trademark Office (USPTO) may grant Patent Term Adjustment to compensate for delays in patent prosecution. However, Patent Term Extension (PTE) is more commonly associated with drug patents to account for regulatory review periods.
-
Patent Term Extension (PTE): For pharmaceutical patents, the Hatch-Waxman Act allows for Patent Term Extension (PTE) to recapture some of the patent term lost during the FDA regulatory review process. This extension is typically up to five years, with a potential additional six months under certain conditions. The eligibility for PTE depends on various factors, including the type of product, the date of approval, and the number of patent terms previously extended for the same product. Without specific information on regulatory submissions and approvals related to this patent and its associated drug products, it is difficult to determine if PTE was applied.
Assuming no significant Patent Term Extension was granted for this specific patent, the original period of exclusivity would have concluded approximately 20 years from its filing date. However, if the patent covers a drug product that received FDA approval and subsequent PTE, the exclusivity period could have been extended. For definitive information regarding any PTE applied, a review of USPTO records and FDA Orange Book listings would be necessary.
Key Takeaways
U.S. Patent 5,583,141 protects a broad class of bicyclic compounds with potassium channel modulating activity. The patent's claims encompass the chemical entities, pharmaceutical compositions, and methods of use for treating cardiovascular, neurological, and inflammatory disorders. Its original 20-year term from filing expired in May 2015. The patent landscape indicates it has served as a foundational patent, influencing subsequent research and intellectual property filings in the area of potassium channel modulators.
Frequently Asked Questions
What is the specific chemical structure protected by Claim 1 of U.S. Patent 5,583,141?
Claim 1 of U.S. Patent 5,583,141 defines a generic formula (I) representing the bicyclic compounds, allowing for various substituents at specific positions on the core bicyclic ring system. The exact chemical structures are determined by the permissible options for these substituents (R1, R2, R3, R4, and Ar), which are detailed within the patent document.
Did any drug products achieve FDA approval based on the patents covered by U.S. Patent 5,583,141?
Information regarding specific FDA-approved drug products directly linked to U.S. Patent 5,583,141 is not provided within this analysis. Confirmation would require consulting FDA databases and the Orange Book.
Can new companies develop potassium channel modulators if U.S. Patent 5,583,141 has expired?
If U.S. Patent 5,583,141 has fully expired without any applicable extensions, new companies can generally develop compounds that fall outside its claims. However, they must ensure their products do not infringe on any subsequently granted patents that may build upon or refine the technology.
What is the significance of Markush claims in U.S. Patent 5,583,141?
Markush claims, as used in Claim 1, are crucial for broadening the scope of protection by defining a group of related chemical compounds through a generic formula with variable substituents. This allows the patent to cover a large family of potential drug candidates rather than just a single specific molecule.
How can one determine if a specific potassium channel modulator infringes on U.S. Patent 5,583,141?
Determining infringement involves a detailed comparison of the specific chemical structure and intended use of the new compound against each claim of U.S. Patent 5,583,141. This analysis requires expert legal and technical interpretation of patent claims and chemical structures.
Citations
[1] U.S. Patent 5,583,141. (1996). Novel bicyclic compounds. [Patent]. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
